Chunlai Lu
Impact in
- Cancer Research top 5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Molecular Biology top 10%
- RNA modifications and cancer
- Circular RNAs in diseases
- Cancer-related gene regulation
- Epigenetics and DNA Methylation
Papers in
-
- RNA modifications and cancer 8
- Epigenetics and DNA Methylation 6
- Cancer-related gene regulation 5
-
- Lung Cancer Treatments and Mutations 7
- Lung Cancer Diagnosis and Treatment 6
- Ferroptosis and cancer prognosis 4
- Co-authors
- Jie Gu (22 shared papers)Fengkai Xu (24 shared papers)Di Ge (14 shared papers)Qiaoliang Zhu (11 shared papers)Di Ge (19 shared papers)Yiwei Chu (7 shared papers)Guangyin Zhao (8 shared papers)Zongwu Lin (6 shared papers)
- Journals
- Tumor Biology (4 papers)Cancer Letters (2 papers)EBioMedicine (2 papers)PLoS ONE (2 papers)Journal of Cancer (2 papers)
- Partner nations
- ChinaUnited StatesMacao
In The Last Decade
Chunlai Lu
40 papers receiving 1.4k citations
Chunlai Lu's Hit Papers
Peers
Comparison fields: 5 of 86
- Cancer Research 567
- Molecular Biology 964
- Oncology 329
- Pulmonary and Respiratory Medicine 311
- Immunology 177
Countries citing papers authored by Chunlai Lu
This map shows the geographic impact of Chunlai Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chunlai Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chunlai Lu more than expected).
Fields of papers citing papers by Chunlai Lu
This network shows the impact of papers produced by Chunlai Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chunlai Lu. The network helps show where Chunlai Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Chunlai Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 41 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity Hit paper breakdown → | 2021 | 416 |
| 2 | 2018 | 99 | |
| 3 | 2012 | 96 | |
| 4 | 2011 | 92 | |
| 5 | 2022 | 80 | |
| 6 | 2013 | 80 | |
| 7 | 2013 | 73 | |
| 8 | 2014 | 68 | |
| 9 | 2008 | 49 | |
| 10 | 2018 | 48 | |
| 11 | 2015 | 38 | |
| 12 | 2022 | 30 | |
| 13 | 2020 | 29 | |
| 14 | 2016 | 29 | |
| 15 | 2018 | 28 | |
| 16 | 2015 | 27 | |
| 17 | 2015 | 25 | |
| 18 | 2021 | 22 | |
| 19 | 2023 | 19 | |
| 20 | Novel methylation-driven genes identified as prognostic indicators for lung squamous cell carcinoma. | 2019 | 16 |
About Chunlai Lu
Chunlai Lu is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Cancer Research, having authored 41 papers that have together received 1.4k indexed citations. Recurring topics across this work include RNA modifications and cancer (8 papers), Esophageal Cancer Research and Treatment (7 papers), Lung Cancer Treatments and Mutations (7 papers), Epigenetics and DNA Methylation (6 papers), Lung Cancer Diagnosis and Treatment (6 papers), Cancer-related gene regulation (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Ferroptosis and cancer prognosis (4 papers). The work is most often cited by research in Cancer Research (567 citations), Molecular Biology (964 citations), Oncology (329 citations), Pulmonary and Respiratory Medicine (311 citations) and Immunology (177 citations). Chunlai Lu has collaborated with scholars based in China, United States and Macao. Frequent co-authors include Jie Gu, Fengkai Xu, Di Ge, Qiaoliang Zhu, Di Ge, Yiwei Chu, Guangyin Zhao, Zongwu Lin, Liyan Jiang and Zhuoan Cheng. Their work appears in journals such as Tumor Biology, Cancer Letters, EBioMedicine, PLoS ONE and Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.